Key Points

HIV Infections and AIDS

• HIV Surveillance:

  • 100% participation of laboratories in LaboVIH in Corsica since 2018 (excluding 2020, the year of the COVID-19 pandemic), higher than the rate observed at the national level;

  • Regional completeness of mandatory reporting (MR) has fluctuated over the past 10 years, lower than the national rate in 2023;

  • Percentage of complete mandatory reporting (both “clinician” and “laboratory” sections) is increasing but remains insufficient.

• HIV testing (SNDS, LaboVIH, VIHTest): activity has been increasing over the past 10 years, regardless of the data source, but remains lower than the national level. The serology rate observed in Corsica is the second lowest in mainland France (LaboVIH).

• HIV diagnosis (DO): the number of new HIV diagnoses has remained generally stable over the past 10 years, with a rate lower than that observed nationally. In Corsica, those affected are older than the national average, with a high proportion of diagnoses made at a late stage (the highest proportion in France).

• HIV incidence (newly infected individuals in 2023): very low regional estimate (2 people), but the number of people living with HIV without knowing their HIV status in Corsica is estimated at 17.

• AIDS diagnosis (AD): low diagnosis rate, lower than the national average, but nearly all cases were unaware of their HIV status prior to the AIDS diagnosis (83% over the 2019–2023 period).

Chlamydia trachomatis infection

• Screening (SNDS): regional rate has been increasing for 10 years, but remains lower than the national rate.

• Diagnosis (SNDS): Regional rate also increasing, equivalent to the national rate.

• Among men, the incidence rate has increased more sharply than the screening rate over the past 5 years, whereas the opposite was true for women.

• At CeGIDD: Chlamydia trachomatis infection is the most commonly diagnosed STI in Corsica and the one most frequently treated at the island’s CeGIDD centers.

Gonococcal infection

• Screening (SNDS): regional rate has been rising for 10 years, nearly equal to the rate observed nationally.

• Diagnosis (SNDS): Regional rate also rising, but lower than the rate observed nationally.

• Between 2019 and 2023 in particular, the incidence rate increased more sharply than the screening rate among women aged 15 to 25.

• SurCeGIDD: despite the participation of the island’s two CeGIDDs in surveillance, data completeness for gonococcal infection as well as for syphilis remains insufficient to analyze trends.

Syphilis

• Screening (SNDS): regional rate has been rising for 10 years, lower than the national rate.

• Diagnosis (SNDS): low regional rate, generally stable over the past 10 years, lower than the national rate.

• Between 2019 and 2023, among men, the incidence rate increased more sharply than the screening rate. Among women, the incidence rate remained generally stable despite increased screening.

Prevention

• Condom sales: In 2023, sales figures in supermarkets and pharmacies remain lower than those observed before the pandemic.

• PrEP use (EpiPhare): a sharp increase in scale since 2021.

• Rollout of the national campaign focused on combined HIV and STI prevention.